Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

NCT06231680 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

132

Enrollment

OTHER_GOV

Sponsor class

Conditions

Lung Cancer, Nonsmall Cell
Esophageal Carcinoma

Interventions

DRUG: Camrelizumab
DRUG: Thalidomide 50mg
DRUG: Thalidomide 100mg
DRUG: Thalidomide 200mg
DRUG: Chemotherapy

Sponsor

Henan Cancer Hospital

Collaborators

[object Object]